HRT Financial LLC Takes $296,000 Position in Crispr Therapeutics AG (NASDAQ:CRSP)

HRT Financial LLC acquired a new position in shares of Crispr Therapeutics AG (NASDAQ:CRSP) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 10,381 shares of the company’s stock, valued at approximately $296,000.

Several other hedge funds have also recently bought and sold shares of CRSP. Resources Investment Advisors Inc. bought a new position in shares of Crispr Therapeutics during the 4th quarter valued at $43,000. Benjamin F. Edwards & Company Inc. raised its stake in shares of Crispr Therapeutics by 96.7% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 1,627 shares of the company’s stock valued at $46,000 after acquiring an additional 800 shares in the last quarter. We Are One Seven LLC bought a new position in Crispr Therapeutics in the fourth quarter worth approximately $57,000. Flagship Harbor Advisors LLC grew its holdings in Crispr Therapeutics by 918.4% in the fourth quarter. Flagship Harbor Advisors LLC now owns 2,709 shares of the company’s stock worth $77,000 after purchasing an additional 2,443 shares during the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its holdings in Crispr Therapeutics by 79.4% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 3,987 shares of the company’s stock worth $112,000 after purchasing an additional 1,765 shares during the last quarter. Hedge funds and other institutional investors own 42.24% of the company’s stock.

A number of research analysts have weighed in on CRSP shares. BidaskClub downgraded shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, December 20th. SunTrust Banks reaffirmed a “buy” rating on shares of Crispr Therapeutics in a research report on Monday, December 31st. Zacks Investment Research raised shares of Crispr Therapeutics from a “hold” rating to a “buy” rating and set a $33.00 target price on the stock in a report on Thursday, January 3rd. Citigroup downgraded shares of Crispr Therapeutics from a “neutral” rating to a “sell” rating and lowered their target price for the company from $28.00 to $21.00 in a report on Tuesday, January 22nd. Finally, Goldman Sachs Group downgraded shares of Crispr Therapeutics from a “buy” rating to a “neutral” rating and decreased their target price for the company from $78.00 to $40.00 in a research note on Monday, January 28th. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating and seven have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $45.75.

In related news, President Rodger Novak sold 85,220 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $40.40, for a total transaction of $3,442,888.00. Following the transaction, the president now owns 1,024,534 shares of the company’s stock, valued at $41,391,173.60. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last ninety days, insiders have sold 108,693 shares of company stock worth $4,381,895. Insiders own 37.70% of the company’s stock.

CRSP traded down $0.76 on Monday, reaching $37.15. The company had a trading volume of 317,037 shares, compared to its average volume of 750,954. Crispr Therapeutics AG has a one year low of $22.22 and a one year high of $73.90. The firm has a market capitalization of $1.99 billion, a PE ratio of -10.80 and a beta of 3.11.

Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Monday, February 25th. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.09). The firm had revenue of $0.10 million for the quarter, compared to analysts’ expectations of $1.56 million. Crispr Therapeutics had a negative net margin of 5,281.08% and a negative return on equity of 48.35%. The firm’s revenue was down 99.7% compared to the same quarter last year. As a group, research analysts anticipate that Crispr Therapeutics AG will post -3.43 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “HRT Financial LLC Takes $296,000 Position in Crispr Therapeutics AG (NASDAQ:CRSP)” was originally published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://www.baseballdailydigest.com/news/2019/04/16/hrt-financial-llc-invests-296000-in-crispr-therapeutics-ag-crsp.html.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.

Further Reading: Growth Stocks

Institutional Ownership by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.